We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ASCLF market cap is 204.88M. The company's latest EPS is CNY -0.1429 and P/E is -1.40.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 173.44M | 35M | 76.88M | 54.09M | 56.6M |
| Operating Income | -165.97M | -173.99M | -199.71M | -422.35M | -322.52M |
| Net Income | -95.97M | -209.24M | -199.02M | -314.84M | -144.72M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 3.43B | 3.07B | 2.83B | 2.66B | 2.49B |
| Total Liabilities | 102.17M | 85.42M | 100.89M | 117.16M | 148.94M |
| Total Equity | 3.32B | 2.98B | 2.73B | 2.54B | 2.34B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | -74.34M | -84.91M | -146.93M | -142.45M | N/A |
| Investing | 602.27M | 132.3M | -274.49M | -1.3B | N/A |
| Financing | -48.22M | -21.67M | -31.1M | -1.42M | N/A |
| Market Cap | 204.88M |
| Price to Earnings Ratio | -1.40 |
| Price to Sales Ratio | 3.58 |
| Price to Cash Ratio | 0.61 |
| Price to Book Ratio | 0.09 |
| Dividend Yield | - |
| Shares Outstanding | 1.01B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | -41.28% |
| 52 Week High | 0.3445 |
| 52 Week Low | 0.1547 |
| Spread (Intraday) | 0.12 (47.71%) |
| Company Name | Ascletis Pharma Inc (PK) |
| Address |
walkers corporate limited grand cayman KY1-9008 |
| Website | https://www.ascletis.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
